ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised – Medical News Asia

Non-Sponsored Content

ASCO 2019 BREAST CANCER TRACK

SPOTLIGHT ON BREAST CANCER

By: Stijn van den Borne, MSc | Last updated: 3 June 2019 | In: Breast Cancer, Conferences, ASCO 2019 Annual Meeting, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies, Translational Research

Breast cancer has always been a front-runner when it comes to the development of novel therapeutic strategies. With the advent of newer targeted- and immunotherapies, oncologists have an increment of therapeutic options to offer their patients – therapies that inherently have lower toxicity risks or the ability to reduce the duration of treatment as well as novel combinations with older therapeutics. The American Society of Clinical Oncology’s (ASCO) 2019 Breast Cancer track offered an extensive look at the latest advancements and updates from on-going trials covering the various subtypes of breast cancer.

Download the PPT

ASCO 2019 Breast Cancer Keywords

Pfizer, Ogivri, AI, docetaxel, Exelixis, CNS metastases, Kadcyla doxorubicin, lapatinib, Tecentriq, RAD001, Tykerb, fulvestrant, trastuzumab-dkst, letrozole, hormonal therapy, ER-positive, MacroGenics, T-DM1, AZ, RB1, vinolrebine, abemaciclib, HER2-negative, Biocon, paclitaxel, epirubicin, ESR1, margetuximab, CDK4/6, TAC, Xeloda, ribociclib, postmenopausal, capivasertib, cobimetinib, GnRH, MEK, endocrine therapy, Faslodex, taxane, Zoladex, cyclophosphamide, Lynparza, Cotellic, trastuzumab, HR-positive, HER2-positive, nab-paclitaxel pembrolizumab, palbociclib, Femara, TNBC, carboplatin, mTor, Ellence, Ibrance, LABC, neratinib, atezolizumab, Afinitor, triptorelin, Novartis, AKT, eribulin mesylate, PD-L1, Kisqali, neoadjuvant, Nerlynx, PARP, Perjeta, NSAI, AstraZeneca, AKT1, Gemzar, Verzenio, OfS, Pharmorubicin, pCR, pertuzumab, Sanofi, chemotherapy, gemcitabine, Aromasin, goserilin, olaparib, Keytruda, PARPi, Puma, cisplatin, Herceptin, #ASCO2019, everolimus, AZD5363, Halaven, Merck, MSD, PR-positive, pyrotinib, Eli Lilly, Mylan, ado-trastuzumab emtansine, exemestane, BRCA, Jiangsu HengRui Medicine, capecitabine, Genentech, premenopausal, Taxotere

ASCO-2019-breast-cancer-TNBC-MBC-ABC-ASCO19-MONALEESA-7-TRINITI-1-FAKTION-TBCRC030-NeoSTOP-ETNA-GeparOLA-KRISTINE-PREDIX-CLEOPATRA-HERITAGE-SOPHIA-NALA-IMpassion-130-Tapur-Colet-1

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).